{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:27:56Z","timestamp":1793986076609,"version":"4.8.0"},"reference-count":87,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Respiratory syncytial virus (RSV) causes a significant burden of acute respiratory illness across all ages, particularly for infants and older adults. Infants, especially those born prematurely or with underlying health conditions, face a high risk of severe RSV-related lower respiratory tract infections (LRTIs). Globally, RSV contributes to millions of LRTI cases annually, with a disproportionate burden in low- and middle-income countries (LMICs). The RSV virion outer capsule contains glycoproteins G and F which are essential for viral entry into respiratory epithelial cells and represent key targets for therapeutics development. The F-glycoprotein has several highly conserved antigenic sites that have proven useful targets for the development of monoclonal antibodies (mAbs) against RSV. Historically, prevention in infants was limited to the mAb palivizumab, which, despite its efficacy, was costly and inaccessible in many regions. Recent advancements include nirsevimab, a long-acting mAb that has shown substantial efficacy in reducing medically attended RSV-related disease in infants, in phase III clinical trials, early regional and national real-world data. In addition, three new vaccines have been approved: two protein subunit vaccines and a messenger RNA vaccine. The vaccines are all licenced for use in older adults, with one also approved as a maternal vaccine. Promising candidates in development include the mAb clesrovimab, which has an extended half-life and high levels in the nasal epithelial lining and high safety and efficacy profiles in late-stage trials. There are also a wide range of vaccine candidates currently in late-stage clinical trials. These developments signify a major advancement in RSV prevention strategies, offering improved protection for high-risk populations. With the ongoing rollout of the recently licenced vaccines and mAbs internationally, the landscape of RSV care is rapidly changing. We also must ensure these advances reach those in LMICs who need these therapies most.<\/jats:p>","DOI":"10.1177\/25151355241310601","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T09:20:31Z","timestamp":1736500831000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":69,"title":["The recent landscape of RSV vaccine research"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7431-9135","authenticated-orcid":false,"given":"Karen","family":"Kelleher","sequence":"first","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"},{"name":"NIHR Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadisha","family":"Subramaniam","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"},{"name":"NIHR Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6350-6557","authenticated-orcid":false,"given":"Simon B.","family":"Drysdale","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX1 2JD, UK"},{"name":"NIHR Oxford Biomedical Research Centre, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"bibr1-25151355241310601","unstructured":"Master Species Lists | ICTV [Internet]. https:\/\/ictv.global\/msl (accessed 18 July 2024)."},{"key":"bibr2-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5021"},{"key":"bibr3-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00062-2"},{"key":"bibr4-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175792"},{"key":"bibr5-25151355241310601","first-page":"83","volume":"372","author":"McLellan JS","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"bibr6-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02316-5"},{"key":"bibr7-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01828-20"},{"key":"bibr8-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106153"},{"key":"bibr9-25151355241310601","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.595297"},{"key":"bibr10-25151355241310601","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01920"},{"key":"bibr11-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.074"},{"key":"bibr12-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-019-0164-9"},{"key":"bibr13-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00580-12"},{"key":"bibr14-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12162-9"},{"key":"bibr15-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052206"},{"key":"bibr16-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1637752"},{"key":"bibr17-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0303"},{"key":"bibr18-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30264-5"},{"key":"bibr19-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piae042"},{"key":"bibr20-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06399-8"},{"key":"bibr21-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00478-0"},{"key":"bibr22-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad188"},{"key":"bibr23-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz683"},{"key":"bibr24-25151355241310601","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v50i12a01"},{"key":"bibr25-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad449"},{"key":"bibr26-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13031"},{"key":"bibr27-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00802-4"},{"key":"bibr28-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2024.07.024"},{"key":"bibr29-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199802000-00006"},{"key":"bibr30-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101337"},{"issue":"11","key":"bibr31-25151355241310601","volume":"2021","author":"Garegnani L","year":"2021","journal-title":"Cochrane Datab Syst Rev"},{"key":"bibr32-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30055-9"},{"key":"bibr33-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102324"},{"key":"bibr34-25151355241310601","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.5.9496"},{"key":"bibr35-25151355241310601","unstructured":"Medscape. Medscape.com. FDA panel nixes licensing request for motavizumab, https:\/\/www.medscape.com\/viewarticle\/722903?&icd=login_success_email_match_fpf (2010, accessed 18 July 2024)."},{"key":"bibr36-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa951"},{"key":"bibr37-25151355241310601","unstructured":"Beyfortus \u2013 opinion on variation to marketing authorisation | European Medicines Agency, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyfortus#overview (accessed 31 December 2024)."},{"key":"bibr38-25151355241310601","unstructured":"CHMP. Annex I Summary of product characteristics- Beyfortus, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/beyfortus-epar-product-information_en.pdf (accessed 31 December 2024)."},{"key":"bibr39-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913556"},{"key":"bibr40-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110275"},{"key":"bibr41-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309189"},{"key":"bibr42-25151355241310601","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.4.2400033"},{"key":"bibr43-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1089\/ped.2024.0025"},{"key":"bibr44-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00215-9"},{"key":"bibr45-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2348135"},{"key":"bibr46-25151355241310601","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12040383"},{"key":"bibr47-25151355241310601","unstructured":"Molina Guti\u00e9rrez M\u00c1, de Miguel Lavisier B, Ruiz Dom\u00ednguez JA, et al. Impact of nirsevimab immunization on RSV infections attended in the pediatric emergency department: first results in a tertiary hospital in Madrid. Enfermedades infecciosas y microbiologia clinica (English ed), https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X24001618(2024), 19 July 2024."},{"key":"bibr48-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-024-05634-z"},{"key":"bibr49-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13311"},{"key":"bibr50-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314885"},{"key":"bibr51-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00321-2"},{"key":"bibr52-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209604"},{"key":"bibr53-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307079"},{"key":"bibr54-25151355241310601","unstructured":"Abrysvo | European Medicines Agency (EMA), https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo (accessed 30 August 2024)."},{"key":"bibr55-25151355241310601","unstructured":"Arexvy | European Medicines Agency (EMA) [Internet], https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arexvy (accessed 30 August 2024)."},{"key":"bibr56-25151355241310601","unstructured":"mResvia | European Medicines Agency (EMA) [Internet], https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mresvia (accessed 30 August 2024)."},{"key":"bibr57-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908380"},{"key":"bibr58-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216480"},{"key":"bibr59-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106062"},{"key":"bibr60-25151355241310601","unstructured":"Respiratory Syncytial Virus (RSV) | FDA [Internet], https:\/\/www.fda.gov\/consumers\/covid-19-flu-and-rsv\/respiratory-syncytial-virus-rsv (accessed 29 August 2024)."},{"key":"bibr61-25151355241310601","unstructured":"Respiratory syncytial virus (RSV) vaccination programme \u2013 GOV.UK, https:\/\/www.gov.uk\/government\/collections\/respiratory-syncytial-virus-rsv-vaccination-programme (accessed 29 August 2024)."},{"key":"bibr62-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305478"},{"key":"bibr63-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae010"},{"key":"bibr64-25151355241310601","unstructured":"Pfizer announces positive top-line data for full season two efficacy of ABRYSVO\u00ae for RSV in older adults | Pfizer, https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-positive-top-line-data-full-season-two (2024, accessed 19 July 2024)."},{"key":"bibr65-25151355241310601","unstructured":"Das R. Update on moderna\u2019s RSV vaccine, mRESVIA (mRNA-1345), in adults \u2a7e60 years of age advisory committee on immunization practices (ACIP), https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-06-26-28\/04-RSV-Adult-Das-508.pdf (accessed 31 December 2024)."},{"key":"bibr66-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad546"},{"key":"bibr67-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae316"},{"key":"bibr68-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab611"},{"key":"bibr69-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae185"},{"key":"bibr70-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213836"},{"key":"bibr71-25151355241310601","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7321a3"},{"key":"bibr72-25151355241310601","unstructured":"Britton A. Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases RSV Vaccination in Older Adults: Work Group Interpretations, https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-02-28-29\/08-RSV-Adults-Britton-508.pdf (accessed 31 December 2024)."},{"key":"bibr73-25151355241310601","unstructured":"Maas BM, Railkar R, Cao X, et al. Pharmacokinetics, serum-neutralising activity, and efficacy against RSV Malri from a phase 1b\/2a study of monocloncal antibody clesrovimab (MK-1654) in infants. Lisbon, https:\/\/resvinet.org\/wp-content\/uploads\/2023\/02\/RSVVW23-Abstract-Booklet.pdf (2023, accessed 19 July 2024)."},{"key":"bibr74-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13290"},{"key":"bibr75-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.883"},{"key":"bibr76-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115851"},{"key":"bibr77-25151355241310601","unstructured":"MSD\u2019s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants \u2013 MSD, https:\/\/www.msd.com\/news\/msds-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-rsv-preventative-monoclonal-antibody-significantly-reduced-incidence-of-rsv-disease-and-hospitalization-in-health\/ (accessed 7 November 2024)."},{"key":"bibr78-25151355241310601","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9090961"},{"key":"bibr79-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.453"},{"key":"bibr80-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz408"},{"key":"bibr81-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2032057"},{"key":"bibr82-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00090-16"},{"key":"bibr83-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac253"},{"key":"bibr84-25151355241310601","unstructured":"Meissa\u2019s Positive Clinical data for the first RSV vaccine designed to protect infants & toddlers, https:\/\/www.meissavaccines.com\/post\/meissa-s-positive-clinical-data-for-the-first-rsv-vaccine-designed-to-protect-infants-toddlers (accessed 2 August 2024)."},{"key":"bibr85-25151355241310601","unstructured":"Codagenix Initiates dosing in Phase 1 Study of intranasal, live-attenuated RSV vaccine, CodaVax\u2122 \u2013 RSV, in a pediatric population | Codagenix [Internet], https:\/\/codagenix.com\/codagenix-initiates-dosing-in-phase-1-study-of-intranasal-live-attenuated-rsv-vaccine-codavax-rsv-in-pediatric-patients\/ (accessed 19 July 2024)."},{"key":"bibr86-25151355241310601","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020367"},{"key":"bibr87-25151355241310601","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30470-9"}],"container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25151355241310601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25151355241310601","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25151355241310601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T03:42:29Z","timestamp":1740973349000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25151355241310601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":87,"alternative-id":["10.1177\/25151355241310601"],"URL":"https:\/\/doi.org\/10.1177\/25151355241310601","relation":{},"ISSN":["2515-1355","2515-1363"],"issn-type":[{"value":"2515-1355","type":"print"},{"value":"2515-1363","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"25151355241310601"}}